Jan 5, 2026 | News, Press Release
JANUARY 5, 2026, NEW YORK – Scientists at the Princeton University Branch of the Ludwig Institute for Cancer Research have identified novel mechanisms by which a metabolic derivative of vitamin A—all-trans retinoic acid—compromises both the body’s normal anti-cancer... Oct 14, 2025 | News, Press Release
Princeton University, Ludwig Institute for Cancer Research and Kayothera, Inc. Announce Publication of Foundational Research in iScience Detailing Novel Approach to Drugging Retinoid Nuclear Receptor Pathway PRINCETON, NJ, October 14, 2025 — A paper published today in... Sep 23, 2025 | News, Press Release
Seattle, WA — September 23, 2025 – Kayothera, Inc. (“Kayothera”), a preclinical therapeutics company developing first-in-class, small molecule inhibitors of the retinoid nuclear receptor pathway, today announces that it has selected KAYO-1732 as a drug development... Jun 21, 2025 | News, Press Release
Seattle, WA — June 21, 2025, Kayothera, Inc., a preclinical-stage therapeutics company pioneering first-in-class, oral inhibitors of the retinoid nuclear receptor pathway, today announced that it has been recognized as one of the winners of the American Diabetes... Oct 22, 2024 | News, Press Release
Yibin Kang, PhD, chairs Scientific Advisory Board that includes experts in translational and early-phase clinical development activities Seattle, WA — October 22, 2024, Kayothera, Inc., a preclinical-stage therapeutics company developing first-in-class, oral, small... Oct 14, 2024 | News, Press Release
Bruce L.A. Carter, PhD, and Paul Sekhri join Board of Directors, adding drug development and operating experience Recent board additions highlight Kayothera’s evolution into pipeline-focused organization with meaningful translational efforts Seattle, WA —...